Literature DB >> 1812633

Status epilepticus. Clinical features, pathophysiology, and treatment.

C Watson1.   

Abstract

During the past two decades, substantial progress has been made in the understanding of the clinical features, classification, pathophysiology, central nervous system consequences, and treatment of status epilepticus. The most commonly used drug regimens have advantages and disadvantages, and, in this review, I recommend a protocol for the treatment of status epilepticus. An important concept in the approach to patients in generalized tonic-clonic status epilepticus is that treatment should be administered within a predetermined time frame. Clinical and experimental research indicates that continuous seizure activity for longer than 60 to 90 minutes may result in irreversible brain damage. As our understanding of the basic mechanisms of neuronal function and seizure generation advances, it is expected that more specific and novel approaches to the treatment of status epilepticus will emerge.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1812633      PMCID: PMC1003112     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  64 in total

1.  Pharmacokinetics and clinical use of parenteral phenytoin, phenobarbital, and paraldehyde.

Authors:  R E Ramsay
Journal:  Epilepsia       Date:  1989       Impact factor: 5.864

2.  Physiologic consequences of status epilepticus.

Authors:  R P Simon
Journal:  Epilepsia       Date:  1985       Impact factor: 5.864

3.  Temporal lobe epilepsy and the Bear-Fedio personality inventory.

Authors:  D M Bear
Journal:  Neurology       Date:  1985-02       Impact factor: 9.910

4.  Self-sustaining limbic status epilepticus induced by 'continuous' hippocampal stimulation: electrographic and behavioral characteristics.

Authors:  E W Lothman; E H Bertram; J W Bekenstein; J B Perlin
Journal:  Epilepsy Res       Date:  1989 Mar-Apr       Impact factor: 3.045

5.  Barbiturate anesthesia in the treatment of status epilepticus: clinical experience with 14 patients.

Authors:  D H Lowenstein; M J Aminoff; R P Simon
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

6.  Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin.

Authors:  D M Shaner; S A McCurdy; M O Herring; A J Gabor
Journal:  Neurology       Date:  1988-02       Impact factor: 9.910

7.  Calcium-binding protein (calbindin-D28k) and parvalbumin immunocytochemistry: localization in the rat hippocampus with specific reference to the selective vulnerability of hippocampal neurons to seizure activity.

Authors:  R S Sloviter
Journal:  J Comp Neurol       Date:  1989-02-08       Impact factor: 3.215

8.  Seizure characteristics, pathology, and outcome after temporal lobectomy.

Authors:  J S Duncan; H J Sagar
Journal:  Neurology       Date:  1987-03       Impact factor: 9.910

9.  Pentobarbital treatment of refractory status epilepticus.

Authors:  M C Rashkin; C Youngs; P Penovich
Journal:  Neurology       Date:  1987-03       Impact factor: 9.910

10.  Response of status epilepticus induced by lithium and pilocarpine to treatment with diazepam.

Authors:  N Y Walton; D M Treiman
Journal:  Exp Neurol       Date:  1988-08       Impact factor: 5.330

View more
  4 in total

1.  Treating status epilepticus.

Authors:  K Wrenn
Journal:  West J Med       Date:  1992-05

2.  Dr watson responds.

Authors:  C Watson
Journal:  West J Med       Date:  1992-05

Review 3.  First-line management of canine status epilepticus at home and in hospital-opportunities and limitations of the various administration routes of benzodiazepines.

Authors:  Marios Charalambous; Holger A Volk; Luc Van Ham; Sofie F M Bhatti
Journal:  BMC Vet Res       Date:  2021-03-04       Impact factor: 2.741

4.  An Intelligent Rule-based System for Status Epilepticus Prognostication.

Authors:  Bahare Danaei; Reza Javidan; Maryam Poursadeghfard; Mohtaram Nematollahi
Journal:  J Biomed Phys Eng       Date:  2021-04-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.